Prothena Co. plc (NASDAQ:PRTA) Shares Acquired by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. increased its stake in shares of Prothena Co. plc (NASDAQ:PRTA) by 0.7% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 327,151 shares of the biotechnology company’s stock after buying an additional 2,189 shares during the quarter. Charles Schwab Investment Management Inc. owned about 0.61% of Prothena worth $4,531,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of PRTA. Purkiss Capital Advisors LLC acquired a new position in Prothena in the fourth quarter valued at approximately $149,000. China Universal Asset Management Co. Ltd. lifted its stake in shares of Prothena by 10.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,409 shares of the biotechnology company’s stock valued at $158,000 after purchasing an additional 1,065 shares during the last quarter. Chicago Partners Investment Group LLC purchased a new position in shares of Prothena during the 4th quarter worth $159,000. Intech Investment Management LLC acquired a new stake in shares of Prothena during the 3rd quarter worth about $210,000. Finally, XTX Topco Ltd purchased a new stake in Prothena in the 3rd quarter valued at about $260,000. Hedge funds and other institutional investors own 97.08% of the company’s stock.

Prothena Price Performance

Shares of Prothena stock opened at $12.65 on Wednesday. Prothena Co. plc has a 12 month low of $11.70 and a 12 month high of $26.36. The stock has a market capitalization of $680.91 million, a price-to-earnings ratio of -5.50 and a beta of -0.02. The firm’s fifty day simple moving average is $14.33 and its 200-day simple moving average is $15.69.

Prothena (NASDAQ:PRTA) last issued its quarterly earnings results on Thursday, February 20th. The biotechnology company reported ($1.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.02) by ($0.06). Prothena had a negative return on equity of 22.67% and a negative net margin of 90.50%. The firm had revenue of $2.12 million for the quarter, compared to analyst estimates of $7.53 million. Analysts anticipate that Prothena Co. plc will post -4.04 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on PRTA shares. Piper Sandler raised their price target on shares of Prothena from $94.00 to $110.00 and gave the company an “overweight” rating in a research report on Wednesday, February 26th. StockNews.com upgraded Prothena from a “sell” rating to a “hold” rating in a report on Monday, February 24th. Bank of America decreased their price objective on Prothena from $26.00 to $22.00 and set a “neutral” rating for the company in a research note on Thursday, December 19th. HC Wainwright restated a “buy” rating and set a $48.00 target price on shares of Prothena in a research note on Friday, February 21st. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Prothena in a report on Friday, February 21st. Three investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat, Prothena presently has an average rating of “Moderate Buy” and a consensus price target of $55.00.

Prothena Profile

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson’s disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer’s disease.